See more : Avanti Acquisition Corp. (AVAN-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Navidea Biopharmaceuticals, Inc. (NAVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Navidea Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Catalyst Biosciences, Inc. (CBIO) Income Statement Analysis – Financial Results
- Inland ZDP Plc (INLZ.L) Income Statement Analysis – Financial Results
- NSD Co., Ltd. (9759.T) Income Statement Analysis – Financial Results
- Maruhachi Securities Co., Ltd. (8700.T) Income Statement Analysis – Financial Results
- Dream Impact Trust (MPCT-UN.TO) Income Statement Analysis – Financial Results
Navidea Biopharmaceuticals, Inc. (NAVB)
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.65K | 531.51K | 915.01K | 26.62K | 322.52K | 1.81M | 21.97M | 13.25M | 6.27M | 1.13M | 78.74K | 597.73K | 10.70M | 9.52M | 7.89M | 7.12M | 6.05M | 5.92M | 5.95M | 6.51M | 4.92M | 7.58M | 9.71M | 9.45M | 5.83M | 5.13M | 1.17M | 1.00M | 900.00K | 100.00K | 100.00K |
| Cost of Revenue | 184.95K | 198.83K | 1.05K | 6.67K | 96.64K | 3.65K | 2.30M | 1.75M | 1.59M | 332.82K | 0.00 | 0.00 | 3.21M | 3.13M | 3.01M | 3.18M | 2.63M | 2.38M | 2.34M | 3.12M | 2.35M | 4.39M | 4.63M | 3.95M | 1.40M | 1.58M | 676.77K | 500.00K | 100.00K | 5.90M | 100.00K |
| Gross Profit | -119.30K | 332.68K | 913.97K | 19.95K | 225.89K | 1.81M | 19.67M | 11.49M | 4.69M | 797.82K | 78.74K | 597.73K | 7.49M | 6.38M | 4.88M | 3.94M | 3.42M | 3.54M | 3.61M | 3.38M | 2.57M | 3.20M | 5.08M | 5.49M | 4.43M | 3.55M | 494.41K | 500.00K | 800.00K | -5.80M | 0.00 |
| Gross Profit Ratio | -181.71% | 62.59% | 99.89% | 74.95% | 70.04% | 99.80% | 89.54% | 86.76% | 74.72% | 70.56% | 100.00% | 100.00% | 70.03% | 67.07% | 61.83% | 55.30% | 56.50% | 59.86% | 60.61% | 52.00% | 52.22% | 42.17% | 52.31% | 58.13% | 75.93% | 69.27% | 42.21% | 50.00% | 88.89% | -5,800.00% | 0.00% |
| Research & Development | 5.97M | 5.14M | 4.93M | 5.34M | 4.22M | 4.51M | 8.88M | 12.79M | 16.78M | 23.71M | 16.89M | 15.15M | 9.22M | 4.97M | 4.51M | 2.87M | 3.80M | 4.03M | 2.45M | 1.89M | 2.32M | 344.68K | 472.73K | 1.31M | 12.96M | 19.66M | 16.08M | 7.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 7.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.96M | 7.45M | 6.69M | 6.28M | 7.70M | 11.17M | 13.01M | 17.26M | 15.54M | 15.53M | 11.18M | 9.55M | 4.58M | 3.24M | 3.41M | 2.84M | 3.08M | 3.16M | 3.15M | 3.10M | 3.27M | 2.32M | 2.96M | 8.21M | 10.55M | 11.16M | 7.75M | 3.60M | 12.00M | 2.30M | 2.90M |
| Other Expenses | 0.00 | -14.12K | -21.86K | -631.21K | 1.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 552.96K | 9.38M | 0.00 | 0.00 | 500.00K | 600.00K | 100.00K | 100.00K |
| Operating Expenses | 13.93M | 12.59M | 11.63M | 10.98M | 11.07M | 15.68M | 21.90M | 30.05M | 32.32M | 39.24M | 28.07M | 24.70M | 13.80M | 8.21M | 7.92M | 41.23M | 6.88M | 7.19M | 5.61M | 5.00M | 5.59M | 2.67M | 3.43M | 10.07M | 32.90M | 30.82M | 23.84M | 11.90M | 12.60M | 2.40M | 3.00M |
| Cost & Expenses | 14.12M | 12.59M | 11.63M | 10.99M | 11.17M | 15.69M | 24.19M | 31.80M | 33.91M | 39.57M | 28.07M | 24.70M | 17.01M | 11.34M | 10.93M | 44.42M | 9.51M | 9.56M | 7.95M | 8.12M | 7.94M | 7.05M | 8.06M | 14.03M | 34.30M | 32.39M | 24.51M | 12.40M | 12.70M | 8.30M | 3.10M |
| Interest Income | 0.00 | 6.00K | 11.34K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 16.10K | 18.84K | 25.04K | 25.76K | 8.80K | 18.75K | 60.86K | 70.98K | 225.47K | 226.66K | 28.87K | 9.42K | 74.26K | 127.66K | 205.96K | 0.00 | 598.83K | 0.00 | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.10M | 6.36K | 0.00 | 25.29K | 30.80K | 168.97K | 4.87K | 1.27M | 3.71M | 2.78M | 1.17M | 13.33K | 554.99K | 1.53M | 1.74M | 2.28M | 1.50M | 1.35M | 334.20K | 186.91K | 31.95K | 11.10K | 24.88K | 0.00 | 189.79K | 0.00 | 83.44K | 200.00K | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 95.82K | 198.83K | 190.58K | 144.51K | 150.39K | 254.59K | 501.37K | 571.42K | 500.18K | 404.18K | 200.22K | 176.54K | 223.46K | 333.75K | 408.35K | 1.81M | 1.22M | 1.29M | 856.01K | 757.78K | 796.83K | 423.12K | 392.50K | 552.96K | 1.12M | 896.52K | 652.62K | -500.00K | -600.00K | -100.00K | -100.00K |
| EBITDA | -13.88M | -11.51M | -10.64M | -10.82M | -10.85M | -13.14M | -6.87M | -21.31M | -31.52M | -38.03M | -27.79M | -24.86M | -49.10M | -35.85M | -2.48M | -2.40M | -2.83M | -2.97M | -1.14M | -853.34K | -2.22M | 955.59K | 1.67M | -4.03M | -27.20M | -26.37M | -22.97M | -11.80M | -12.10M | -8.40M | -3.10M |
| EBITDA Ratio | -21,134.32% | -2,337.93% | -1,170.60% | -41,184.60% | -1,722.58% | -541.05% | -20.54% | -114.85% | -448.72% | -3,399.73% | -35,547.39% | -3,998.82% | 345.15% | 341.96% | -27.82% | -482.39% | -36.85% | -37.03% | 1.57% | -12.95% | -45.50% | 20.93% | 17.16% | -46.74% | -469.25% | -551.70% | -1,960.93% | -1,180.00% | -1,344.44% | -8,400.00% | -3,100.00% |
| Operating Income | -14.05M | -12.06M | -10.71M | -10.96M | -10.85M | -13.88M | -2.22M | -18.55M | -27.63M | -38.44M | -27.99M | -24.10M | -6.31M | -1.82M | -3.04M | -1.76M | -3.46M | -3.64M | -2.00M | -1.61M | -2.99M | -352.21K | 1.29M | -4.58M | -28.47M | -27.26M | -23.34M | -11.40M | -11.80M | -8.20M | -3.00M |
| Operating Income Ratio | -21,402.08% | -2,269.07% | -1,170.60% | -41,184.60% | -3,363.29% | -766.50% | -10.12% | -140.01% | -440.38% | -3,399.73% | -35,547.39% | -4,032.67% | -58.98% | -19.17% | -38.57% | -24.74% | -57.19% | -61.56% | -33.58% | -24.75% | -60.82% | -4.64% | 13.25% | -48.50% | -488.08% | -531.69% | -1,993.02% | -1,140.00% | -1,311.11% | -8,200.00% | -3,000.00% |
| Total Other Income/Expenses | -1.13M | 345.52K | -10.51K | 17.68K | -5.32M | -3.91M | 2.77M | -10.32M | -13.14M | -4.26M | -1.17M | -943.16K | -37.20M | 1.82M | -2.12M | -3.33M | -1.28M | -1.28M | -1.24M | -10.38K | 28.48K | 369.77K | 371.83K | 386.58K | 26.50K | 1.92M | 276.87K | 900.00K | 900.00K | 300.00K | 200.00K |
| Income Before Tax | -15.18M | -11.71M | -10.72M | -10.94M | -16.17M | -17.79M | -14.31M | -28.76M | -35.73M | -42.70M | -29.16M | -25.05M | -49.96B | -39.61B | -5.17B | -5.09B | -4.74B | -4.93B | -3.24M | -1.62M | -2.96M | 17.57K | 1.66M | -4.19M | -28.44M | -25.34M | -23.07M | -10.50M | -10.90M | -7.90M | -2.80M |
| Income Before Tax Ratio | -23,117.58% | -2,204.06% | -1,171.75% | -41,118.20% | -5,013.18% | -982.62% | -65.13% | -217.05% | -569.36% | -3,776.61% | -37,030.66% | -4,190.46% | -466,936.68% | -416,112.49% | -65,509.12% | -71,415.40% | -78,353.34% | -83,266.70% | -54.36% | -24.91% | -60.24% | 0.23% | 17.08% | -44.41% | -487.63% | -494.19% | -1,969.38% | -1,050.00% | -1,211.11% | -7,900.00% | -2,800.00% |
| Income Tax Expense | 0.00 | 16.04K | -81.74K | 707.00 | 2.75K | -4.06M | -648.00K | -436.05K | 2.68M | 2.37M | 43.33M | -7.88M | 43.65M | 37.45M | 2.12M | -32.20M | 1.28M | 1.28M | 1.54M | 187.87K | -726.00 | 2.62K | -194.07K | -407.40K | -435.54K | -4.02M | -2.37M | 400.00K | 200.00K | 0.00 | -200.00K |
| Net Income | -15.18M | -11.73M | -10.64M | -10.95M | -16.13M | 74.95M | -14.31M | -27.56M | -35.73M | -42.70M | -29.16M | 5.61M | -49.96M | -39.61M | -5.17M | -5.09M | -4.74M | -4.93M | -3.54M | -1.80M | -2.96M | 14.95K | 1.84M | -4.17M | -28.03M | -23.25M | -20.97M | -10.80M | -10.80M | -8.00M | -2.60M |
| Net Income Ratio | -23,117.58% | -2,207.08% | -1,162.82% | -41,120.85% | -5,000.12% | 4,139.67% | -65.13% | -208.03% | -569.36% | -3,776.61% | -37,030.66% | 939.05% | -466.94% | -416.11% | -65.51% | -71.42% | -78.35% | -83.27% | -59.49% | -27.63% | -60.23% | 0.20% | 18.95% | -44.19% | -480.61% | -453.33% | -1,790.42% | -1,080.00% | -1,200.00% | -8,000.00% | -2,600.00% |
| EPS | -0.59 | -0.40 | -0.45 | -0.76 | -1.89 | 9.40 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.45 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| EPS Diluted | -0.56 | -0.40 | -0.45 | -0.76 | -1.89 | 9.00 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.31 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| Weighted Avg Shares Out | 29.34M | 29.34M | 23.90M | 14.39M | 8.53M | 8.08M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.29M | 1.29M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
| Weighted Avg Shares Out (Dil) | 30.90M | 29.34M | 23.90M | 14.39M | 8.53M | 8.30M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.30M | 1.32M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB —from the...
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer.
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced Dana J Moss, JD has joined the Company's Board of Directors, adding depth in...
Navidea Biopharmaceuticals rejects ProPhase Labs offer
Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech,...
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
DUBLIN, Ohio--(BUSINESS WIRE)--Following the Company's Fix, Fund, Propel approach, the proposal substantially undervalues Navidea and is not in the best interests of stockholders.
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share...
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment.
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update.
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received a Notice (the “Notice”) on June 1, 2023 from the NYSE...
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L.
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down.
Source: https://incomestatements.info
Category: Stock Reports